A healthcare professional looking for the latest evidence on a treatment pathway, a hospital procurement officer evaluating a supplier, or a patient researching options before a consultation: all three now start with an AI query. LLMs synthesize clinical literature, regulatory information, and industry sources in seconds. If your pharma brand or specialty does not appear in these syntheses, you are losing influence before the conversation even begins.
The pharmaceutical sector has historically relied on medical sales reps, congresses, and peer-reviewed publications to build credibility. These channels remain essential. But LLMs have added a new layer: an algorithmic gatekeeper that filters what healthcare professionals encounter first. That gatekeeper is shaped by your public content, your citations in credible sources, and the consistency of your scientific narrative across the web.
AISOS audits your AI visibility in therapeutic areas that matter to your business, identifies where competitors are cited instead of you, and deploys a signal strategy grounded in scientific rigor and regulatory compliance. AI visibility in pharma is not about gaming the system. It is about making sure your evidence base is findable by machines as well as humans.
How LLMs handle medical and pharma queries
LLMs are trained on enormous corpora that include clinical guidelines, medical journals, regulatory documents, and health news. When a healthcare professional asks about a drug class, a mechanism of action, or a treatment comparison, the model draws on that corpus to generate a structured answer. The brands and products that appear in those answers are the ones most frequently cited in the underlying sources.
This creates a structural bias: companies with a strong publication strategy, active medical affairs teams producing accessible content, and consistent presence in clinical databases are overrepresented. Companies that confine their scientific content to closed congress presentations and paywalled journals are nearly invisible to LLMs.
Understanding this dynamic is the first step. The second is acting on it without compromising scientific integrity or regulatory compliance. AISOS works within those constraints to identify the content gaps and signal deficits that are limiting your AI presence in your priority therapy areas. Download our AI SEO checklist 2026 to benchmark your current position.
Medical affairs and AI: a new mandate
Medical affairs teams have always been responsible for translating complex science into accessible information for healthcare professionals. That mandate now extends to AI systems. LLMs need structured, accessible, well-cited scientific content to form accurate representations of your therapy areas and products.
Plain-language summaries of clinical data, accessible disease state education, structured comparisons of treatment modalities: this type of content serves both HCPs who prefer concise formats and the LLMs that will synthesize information on their behalf. It is not a replacement for peer-reviewed publication. It is a complementary layer that ensures your science reaches algorithmic systems as well as human readers.
AISOS works with your medical affairs and regulatory teams to identify what can be published, in what format, and through which channels to maximize legitimate AI visibility. We help you go from invisible to cited without crossing any compliance lines. Read more about the underlying methodology in our AEO guide.
Patient journeys and AI: the upstream opportunity
Patients increasingly use AI to understand their diagnosis, research treatment options, and prepare questions for their physicians. These patient-facing AI interactions have an indirect but real commercial impact: patients who arrive at consultations already informed about a therapy class are more likely to have a substantive conversation about it.
Patient education content, accessible disease information, and FAQ formats are particularly well-suited to AI ingestion. They use plain language, structured formats, and cover the exact questions patients ask. Investing in this content layer creates value for patients directly and builds AI visibility as a secondary benefit.
For global pharma companies operating across markets, AI visibility in patient-facing queries also varies by language and region. Our Brussels practice covers European markets specifically. See how we approach regional AI visibility in our Brussels AI visibility hub, which illustrates the multilingual complexity relevant to European pharma operations.
Measuring AI visibility in regulated environments
Measuring AI visibility in pharma requires a different framework than standard digital analytics. You cannot track an LLM referral the way you track a Google click. What you can measure is mention rate: how often your brand, product, or therapy area appears when you systematically query major LLMs on relevant clinical and commercial topics.
AISOS runs systematic LLM audits across GPT-4, Claude, Gemini, and Perplexity. We cover the queries your target audiences actually use: HCP queries, patient queries, payer queries, procurement queries. The output is a mention rate by query type, a competitive benchmark, and a prioritized action plan that respects your regulatory environment.
This baseline measurement, repeated quarterly, gives you a metric that is both actionable and legally defensible. You are not claiming AI is driving prescriptions. You are measuring how visible your scientific narrative is to the systems that now shape information access in healthcare. Contact us to start with a free audit.